The New Bespak: Championing Sustainability with Chris Hirst

Sustainability Industry trends

resource : Insight

Sustainability is an increasing focus within the pharmaceutical industry. In the world of inhalation and nasal drug delivery in particular, changing legislation around sustainable practices poses challenges for manufacturers and formulators. There is a requirement to explore alternative propellants and embrace sustainable solutions while continuing to offer patients the medical care they need.

Chris Hirst, CEO of Bespak, talks to us about key developments in the inhalation industry, how the formation of leading global contract development and manufacturing organisation (CDMO) Bespak can provide support in navigating these changes, and his ambitions for the future of sustainable inhaled and nasal drug delivery.

What developments are you most excited about in the field of nasal and inhaled drug delivery?

As an industry and as a planet, 37 years ago we famously signed a treaty designed to protect our ozone layer from chlorofluorocarbons (CFCs) and transition to less harmful hydrofluorocarbon (HFC) propellants. Propellants are a key component of pressurised metered dose inhalers (pMDIs) and pMDIs are the most-used treatments for respiratory illness globally. The global pMDI market was valued at $16.3 billion in 2021, and that’s growing significantly – we expect it to reach $22.1 billion by 2031. Put simply, almost everyone knows someone who uses a pMDI. 

While the HFC propellants we use today have a high global warming potential (GWP), there are promising alternative low GWP propellants that have been developed. The industry urgently needs to act and move to more climate-friendly propellants for our patients and our planet. We are an industry that is at the forefront of this change. At Bespak, collaborating with our partners to bring greener, low GWP propellants to a product used by so many is something we are proud to be a part of.

Can you tell us about Bespak and its impressive legacy in nasal and inhaled drug delivery?

Bespak has a long-standing, highly credible legacy. It is a brand that is known all over the world. We have three sites: North Carolina in the US, and Holmes Chapel and King's Lynn in the UK.

Historically, Bespak is the name used by our King’s Lynn site. As a leading inhalation player, we’ve been manufacturing components at King’s Lynn since the late 1960s, when we produced valves for one of the first pMDI products. Now we are known for being a leading global supplier of pMDI dosing valves and actuators, and complex dry powder inhaler (DPI) devices.

In North Carolina, we have over 20 years’ experience in developing inhalation products. We work primarily in formulation, but more specifically, our early-stage laboratory investigates formulation feasibility, and has a well-established reputation for analytical method development and analytical studies.

Meanwhile, the Holmes Chapel site has been around since the 1940s, and there we have been manufacturing inhalers since the 1960s. Our legacy spans generations of experts, with some of our workforce having been with us for 30 – 40 years, meaning we effectively have grandparents, their children and even their grandchildren working in the company. As a result, our team has an unmatched depth of understanding of producing inhaled products, and the fully integrated process as a whole.

Read the full article here

Stay in touch

We’ll send you regular updates from Bespak®.